Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AbCellera BiologicsABCL -4.02%60 Equity-to-Asset is 0.72 as of Mar. 2026, which is 6% below its 10-year median of 0.77. GuruFocus rates ABCL with a GF Score™ of 60/100 and a GF Value™ of $5.23 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, AbCellera Biologics ranks better than 55.37% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. AbCellera Biologics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $938.08 Mil. AbCellera Biologics's Total Assets for the quarter that ended in Mar. 2026 was $1,307.11 Mil.
Therefore, AbCellera Biologics's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.72.
The historical rank and industry rank for AbCellera Biologics's Equity-to-Asset or its related term are showing as below:
ABCL'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44 Med: 0.77 Max: 0.85
Current: 0.72
During the past 8 years, the highest Equity to Asset Ratio of AbCellera Biologics was 0.85. The lowest was 0.44. And the median was 0.77.
ABCL's Equity-to-Asset is ranked better than 55.37% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs ABCL: 0.72
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
AbCellera Biologics Equity-to-Asset Related Terms
AbCellera Biologics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABCL vs AGIO, KOD, IMNM: Equity-to-Asset Comparison
For the Biotechnology subindustry, AbCellera Biologics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
AbCellera Biologics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (ABCL) has a Equity-to-Asset of 0.72 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on AbCellera Biologics and its competitors. This is near median its historical median of 0.77. Over the past decade, AbCellera Biologics' Equity-to-Asset has ranged from 0.44 to 0.85. According to the industry distribution chart, AbCellera Biologics ranks #632 out of 1416 companies in the Biotechnology industry, placing it in the top 44.6%.
Is AbCellera Biologics' Equity-to-Asset too high?
AbCellera Biologics' current Equity-to-Asset of 0.72 is near median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 0.85. The Biotechnology industry median Equity-to-Asset is 0.68. AbCellera Biologics' value of 0.72 is 5.9% above this industry median. Based on the distribution chart, AbCellera Biologics ranks #632 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AbCellera Biologics has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Equity-to-Asset compare to AGIO and KOD?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #632 out of 1416 companies for Equity-to-Asset. This puts AbCellera Biologics in the upper half of its industry. The industry median Equity-to-Asset is 0.68. AbCellera Biologics' value of 0.72 is 5.9% above this benchmark. Historically, AbCellera Biologics' own Equity-to-Asset has ranged from 0.44 to 0.85 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 0.68, AbCellera Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbCellera Biologics's current Equity-to-Asset of 0.72 is 5.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on AbCellera Biologics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current Equity-to-Asset is 0.72, which is near median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Fairly Valued. The stock's GF Value™ is $5.23, compared to a current price of $5.73 — trading 9.6% above its estimated fair value. The current Equity-to-Asset is 0.72, which is near median its 10-year median of 0.77 and 5.9% above the Biotechnology industry median of 0.68. AbCellera Biologics' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Equity-to-Asset is 0.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $5.73 is trading 9.6% above its estimated GF Value™ of $5.23.
GuruFocus considers AbCellera Biologics to be Fairly Valued.
Key valuation signals for ABCL:
Equity-to-Asset: 0.72 (near median its 10-year median of 0.77)
GF Value™: $5.23 vs. price of $5.73 (9.6% above fair value)
Industry Position: 5.9% above the Biotechnology median (#632 of 1416)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
60GF Score
Get the complete analysis for ABCL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
